Treatments such as metformin, which also aids in the regulation of type 2 diabetes, as well as GS-0976 and MK-4074—potent inhibitors of ACC-1 and ACC-2—help to better understand the critical role that these enzymes play in the management of patients with NAFLD [12,13,14]. Here, ACACA is linked to metabolic dysfunction-associated steatotic liver disease.